An Open-Label, Multi-Cohort Phase IIb Clinical Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Latest Information Update: 14 Jan 2026
At a glance
- Drugs ABP 1011 T (Primary)
- Indications Bladder cancer; Cervical cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms ABP1011T-03
- Sponsors AB Pharma
Most Recent Events
- 14 Jan 2026 New trial record